A Novel “Slit Side View” Method to Evaluate Fluid Dynamics during Phacoemulsification

Due to recent technical advances in cataract surgeries, there has been a significant improvement in the safety and surgical outcomes of phacoemulsification. However, the corneal endothelium can be damaged during phacoemulsification by multiple factors. Therefore, we used a slit lamp to analyze the fluid dynamics of ophthalmic viscosurgical devices (OVDs) in the anterior chamber during phacoemulsification. In this experimental study, extracted porcine eyes were injected with OVDs stained with fluorescein through a side port of the eye and then fixed on a slit lamp microscope. After inserting a phaco tip, phacoemulsification simulation was then performed on the iris plane. Subsequent movements of OVDs in the anterior chamber were observed during the procedure by using a slit lamp microscope. Aspiration and removal of cohesive OVDs from the inside of the anterior chamber occurred within a few seconds after the ultrasonic vibration. Aspiration of dispersive OVDs occurred gradually, with some of the OVDs remaining on the side of the anterior chamber side in an irregular shape. This shape enabled the OVD to trap the air, thereby preventing the air from directly touching the corneal endothelium. Viscoadaptive OVDs remained inside the anterior chamber as a lump, with the infusion solution flowing between the corneal endothelium and the OVD, thus leading to the eventual aspiration of the OVD. Viscous dispersive OVDs remained as a lump between the corneal endothelium and the phaco tip. However, once the infusion solution flowed between the cornea and the OVD, the OVD detached from the corneal endothelium, indicating that this type would likely be aspirated and removed. This method, termed the “slit side view,” enables viewing of the movement of OVDs during surgery, as well as observation of the fluid dynamics in the anterior chamber

Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry)

Introduction Given an increasing use of dipeptidyl peptidase-4 (DPP-4) inhibitors to treat patients with type 2 diabetes mellitus in the real-world setting, we conducted a prospective observational study (Japan-based Clinical Research Network for Diabetes Registry: J-BRAND Registry) to elucidate the safety and efficacy profile of long-term usage of alogliptin.Research design and methods We registered 5969 patients from April 2012 through September 2014, who started receiving alogliptin (group A) or other classes of oral hypoglycemic agents (OHAs; group B), and were followed for 3 years at 239 sites nationwide. Safety was the primary outcome. Symptomatic hypoglycemia, pancreatitis, skin disorders of non-extrinsic origin, severe infections, and cancer were collected as major adverse events (AEs). Efficacy assessment was the secondary outcome and included changes in hemoglobin A1c (HbA1c), fasting blood glucose, fasting insulin and urinary albumin.Results Of the registered, 5150 (group A: 3395 and group B: 1755) and 5096 (3358 and 1738) were included for safety and efficacy analysis, respectively. Group A patients mostly (>90%) continued to use alogliptin. In group B, biguanides were the primary agents, while DPP-4 inhibitors were added in up to ~36% of patients. The overall incidence of AEs was similar between the two groups (42.7% vs 42.2%). Kaplan-Meier analysis revealed the incidence of cancer was significantly higher in group A than in group B (7.4% vs 4.8%, p=0.040), while no significant incidence difference was observed in the individual cancer. Multivariate Cox regression analysis revealed that the imbalanced patient distribution (more elderly patients in group A than in group B), but not alogliptin usage per se, contributed to cancer development. The incidence of other major AE categories was with no between-group difference. Between-group difference was not detected, either, in the incidence of microvascular and macrovascular complications. HbA1c and fasting glucose decreased significantly at the 0.5-year visit and nearly plateaued thereafter in both groups.Conclusions Alogliptin as a representative of DPP-4 inhibitors was safe and durably efficacious when used alone or with other OHAs for patients with type 2 diabetes in the real world setting